Olfactory Training in Mild Cognitive Impairment

Status: Recruiting
Location: See location...
Intervention Type: Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Sense of smell tends to decline in individuals with early Alzheimer's disease, typically earlier than when other senses and thinking abilities begin to decline. Memory for new odors is particularly diminished in these individuals. Existing treatments for AD do not improve these symptoms. A targeted treatment for improving sense of smell, called 'Olfactory Training', has been used to improve sense of smell in people with various forms of smell loss, though it is not known whether it can improve smell abilities and thinking abilities in patients who are at high risk of developing Alzheimer's disease. The investigators will conduct a randomized clinical trial with patients who have mild cognitive impairment (MCI). This is an early phase of memory loss that is worse than normal aging and may precede Alzheimer's disease. Patients will be randomized to either olfactory memory training or visual memory training for 3 months, with a final follow-up visit at 6 months. This study will attempt to determine if olfactory training is a useful for improving smell abilities, thinking abilities, and everyday functioning by examining change in these outcomes over time.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 55
Maximum Age: 89
Healthy Volunteers: f
View:

• Age 55-89 at the time of informed consent.

• Montreal Cognitive Assessment score \>=17.

• Subjective cognitive complaints, i.e., memory or other cognitive complaints, e.g., naming/language.

• Meets criteria for cognitive impairment (CI), including either early mild cognitive impairment (eMCI) or late mild cognitive impairment (lMCI), defined as memory function documented by scoring below the education adjusted cutoff on the Logical Memory II subscale (Story A, Delayed Paragraph Recall) from the Wechsler Memory Scale (WMS) - III (the maximum score is 25). The criteria for MCI (includes eMCI and lMCI) are as follows: eMCI is defined by a WMS-III Logical memory delayed recall score of 3-6 with 0-7 years of education, score of 5-9 with 8-15 years of education, and score of 9-11 with 16 or more years of education. lMCI is defined by a WMS-III Logical Memory delayed recall score ≤ 2 with 0-7 years of education, score ≤ 4 with 8-15 years of education, and score ≤ 8 with ≥ 16 years of education.

• An informant (relative, friend, other caregiver) who contacts the participant at least weekly is required to provide information about the participant's functioning. If the informant drops out, an alternate informant can be designated by the participant.

Locations
United States
New York
New York State Psychiatric Institute
RECRUITING
New York
Contact Information
Primary
Jeffrey N Motter, PhD
jeffrey.motter@nyspi.columbia.edu
6467748654
Time Frame
Start Date: 2025-08-07
Estimated Completion Date: 2028-03-31
Participants
Target number of participants: 30
Treatments
Active_comparator: Olfactory Memory Training
Active_comparator: Visual Memory Training
Sponsors
Collaborators: Alzheimer's Association
Leads: Jeffrey Motter

This content was sourced from clinicaltrials.gov

Similar Clinical Trials